top of page
IV in hospital hallway
sanofi_white-OJqMZU4G.gif

Challenge: 

How might we envision bold, new possibilities for large-volume drug delivery devices that are digitally enabled and connected, user-centric, and respond to the evolving needs of patients?

b2-C599LBkf.png

Research showed:
Sustainability gap in OBDS materials
PLA/PCL biocomposites enable eco-friendly disposables
Clinical look increases anxiety + stigma
Fashion-integrated wearables improve acceptance

image.png
image.png
image.png

A gap analysis revealed that current devices are lacking:

  • Support for >10 mL volumes delivered comfortably
     

  • Currently, rigid, medical form factors aren’t discreet or wearable for long durations 

     

  • There is limited accessibility for users with visual, motor, or cognitive impairments

     

  • There is high environmental impact, and designs induce fear with limited flexibility

Interviews

b2-C599LBkf.png

Examples of questions included: 


​

​

  • What are you being treated for?
     

  • How often do you use an OBDS? Where?
     

  • What were your initial thoughts or concerns before starting OBDS?
     

  • Do you use any apps or digital tools to support your treatment?
     

  • How easy or difficult is it to apply and remove the OBDS?
     

  • Is there anything you keep track of manually (vitals, feelings, symptoms, etc) during the process?

  • How would you like to know your dose is done? (visually, haptics etc…) 
     

  • Would you like the OBDS to be more customizable (e.g., color, shape)?
     

  • If you could design an ideal OBDS, what would it look and feel like?

image.png

Prototype

From user interviews and research, I decided a patch design with an optional belt would be ideal for users who wanted a versatile fit. This design also includes TENS numbing technology, vital tracking, and a retractable needle. 

image.png
Image from iOS.jpg

Patient Personas 

Maya

48 years old

 

Wife, and mother of two childrenHigh school teacher

 

Avid hiker

 

Diagnosed with HER2-positive breast cancer

 

After several IV infusions at the hospital, Maya is starting self-subcutaneous injections into the thigh, using a fixed-dose formulation to be administered over 8 minutes.

image.png

User Journey

image.png
b4-BOJ1lZZy.png
image.png
image.png

Materials 

image.png
image.png
image.png

Mobile Design

image.png
image.png

Features

- Onboarding and help guides

- Dashboard customization

- Integration with EHRData sharing/exporting

- Journal entries

- Notification and alert setting

bottom of page